Rajkumar S Vincent, Kumar Shaji
Division of Hematology, Mayo Clinic, Rochester, MN.
Division of Hematology, Mayo Clinic, Rochester, MN.
Mayo Clin Proc. 2016 Jan;91(1):101-19. doi: 10.1016/j.mayocp.2015.11.007.
The diagnosis and treatment of multiple myeloma has changed dramatically in the past decade. The disease definition has been updated to include highly specific biomarkers in addition to established markers of end-organ damage. The staging system has been revised to combine both measures of tumor burden and disease biology. Advances in therapy have resulted in a marked improvement in overall survival. New drugs introduced in the past few years include carfilzomib, pomalidomide, panobinostat, ixazomib, elotuzumab, and daratumumab. In this review, we outline the current approach to the diagnosis, prognosis, and management of multiple myeloma.
在过去十年中，多发性骨髓瘤的诊断和治疗发生了巨大变化。疾病定义已更新，除了既定的终末器官损伤标志物外，还纳入了高度特异性的生物标志物。分期系统已修订，以结合肿瘤负荷和疾病生物学的测量指标。治疗进展使总生存期显著改善。过去几年引入的新药包括卡非佐米、泊马度胺、帕比司他、伊沙佐米、埃罗妥珠单抗和达雷妥尤单抗。在本综述中，我们概述了多发性骨髓瘤诊断、预后和管理的当前方法。
